Proxy Votes Now

Home › Activist investors › BML Capital

BML Capital

Campaign activist. Positions and campaigns from BML Capital’s SEC filings. Updated November 20, 2026.

Filer entities
BML Capital Management, LLC
SEC CIK
1616824 (BML Capital Management, LLC)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Nov 6, 2026: 18 US-listed positions reported; 11 of 1% or more of a company without a 13D are listed below.
11current positions
6new or changed in 90 days
0active campaigns
0campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (11)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
PMV Pharmaceuticals, Inc. 13.71%7,330,000 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 14, 2026 Apr 24, 2024 Increased Nov 6, 2026 ▲ 3.74 pts Increased 13F: none stated
Atea Pharmaceuticals, Inc. 8.42%6,753,658 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 10, 2026 Jul 24, 2023 Decreased Nov 6, 2026 ▼ 0.25 pts Decreased 13F: none stated
Aclaris Therapeutics, Inc. 6.91%10,955,000 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Oct 30, 2026 Feb 2, 2024 Decreased Nov 6, 2026 ▼ 1.23 pts Decreased 13F: none stated
Connect Biopharma Holdings Limited 6.14%3,864,400 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Jul 31, 2026 Nov 10, 2025 Increased Nov 6, 2026 ▲ 5.23 pts Increased 13F: none stated
Seer, Inc. 3.95%2,186,587 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 5, 2026 Nov 6, 2026 — — New 13F: none stated
Oramed Pharmaceuticals Inc. 2.13%884,392 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 10, 2026 Apr 14, 2023 Increased Nov 6, 2026 ▲ 0.04 pts Increased 13F: none stated
Outset Medical Inc. 13.59%2,519,701 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of May 1, 2026 Feb 3, 2026 — 0.00 pts — 13F: none stated
Instil Bio, Inc. 9.52%645,600 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 11, 2026 Apr 24, 2024 — 0.00 pts — 13F: none stated
Tilly's, Inc. 7.14%2,150,000 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of May 2, 2026 Feb 13, 2023 — 0.00 pts — 13F: none stated
Pliant Therapeutics, Inc. 2.50%1,546,137 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 7, 2026 Feb 3, 2026 — 0.00 pts — 13F: none stated
Ikena Oncology, Inc. 1.77%200,730 shares 13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Jul 31, 2026 Aug 7, 2024 — 0.00 pts — 13F: none stated

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of BML Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Seer, Inc. · BML Capital first disclosed Nov 6, 2026 · 1 other filing
HolderFormDateStake
BML Investment Partners, L.P. Schedule 13D Nov 2, 2026 4.7%
Pliant Therapeutics, Inc. · BML Capital first disclosed Feb 3, 2026 · 5 other filings
HolderFormDateStake
Deep Track Capital, LP Schedule 13G Aug 14, 2025 6.4%
Point72 Asset Management, L.P. Schedule 13G Sep 4, 2025 6.7%
Woodline Partners LP Schedule 13G Nov 14, 2025 7.3%
Morgan Stanley Schedule 13G Jan 8, 2026 0.9%
Kenneth Griffin Schedule 13G Jan 22, 2026 4.9%
Outset Medical Inc. · BML Capital first disclosed Feb 3, 2026 · 5 other filings
HolderFormDateStake
BML Investment Partners, L.P. Schedule 13G Jan 14, 2026 9.4%
Bank of America Corp /De/ Schedule 13G Feb 11, 2026 5.2%
PFM Health Sciences, LP Schedule 13G Feb 17, 2026 2.9%
Woodline Partners LP Schedule 13G May 15, 2026 1.6%
BlackRock, Inc. Schedule 13G Jul 29, 2026 2.0%
Atea Pharmaceuticals, Inc. · BML Capital first disclosed Jul 24, 2023 · 1 other filing
HolderFormDateStake
Tang Capital Schedule 13D Nov 28, 2023 4.8%
Tilly's, Inc. · BML Capital first disclosed Feb 13, 2023 · 1 other filing
HolderFormDateStake
Fund 1 Investments, LLC Schedule 13D Jun 2, 2023 24.9%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.